Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01258998 · ClinicalTrials.gov registry record · Phase 2
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
A Phase 2 study of Anaplastic Large Cell Lymphoma and Angioimmunoblastic T-cell Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01258998 is a Phase 2 study of Anaplastic Large Cell Lymphoma and Angioimmunoblastic T-cell Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants, roughly in line with the 58-participant average among 25 other Anaplastic Large Cell Lymphoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT01258998, a Phase 2 study of Anaplastic Large Cell Lymphoma and Angioimmunoblastic T-cell Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG Akt inhibitor MK2206
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01258998
The ClinicalTrials.gov registry entry for NCT01258998 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 58-participant average among 25 other Anaplastic Large Cell Lymphoma trials with a reported enrollment target. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Anaplastic Large Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01258998 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01258998 about?
NCT01258998 is a clinical study titled "Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma". This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01258998?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2010-12. Estimated completion is 2015-08.
What conditions does trial NCT01258998 study?
This clinical trial studies the following conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue.
What interventions are being tested in trial NCT01258998?
The interventions under investigation include: laboratory biomarker analysis (OTHER), Akt inhibitor MK2206 (DRUG).
Who is sponsoring clinical trial NCT01258998?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01258998 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaplastic Large Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
COMPLETED · Phase 2
-
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
COMPLETED · Phase 2
-
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
COMPLETED · Phase 2
-
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.